Cargando…

A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?

Conflicting evidence exists about the effect of angiotensin‐converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) on COVID‐19 clinical outcomes. We aimed to provide a comprehensive/updated evaluation of the effect of ACEIs/ARBs on COVID‐19‐related clinical outcomes, including exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurdi, Amanj, Abutheraa, Nouf, Akil, Lina, Godman, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575889/ https://www.ncbi.nlm.nih.gov/pubmed/33084232 http://dx.doi.org/10.1002/prp2.666

Ejemplares similares

An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
por: Kurdi, Amanj, et al.
Publicado: (2022)

Validity of Pneumonia Severity Assessment Scores in Africa and South Asia: A Systematic Review and Meta-Analysis
por: Al Hussain, Sarah Khalid, et al.
Publicado: (2021)

Lessons from the failure of implementing the ‘Better Care Better Value’ prescribing indicator for renin–angiotensin system drugs in England: a qualitative study of general practitioners’ perceptions using behavioural change framework
por: Kurdi, Amanj, et al.
Publicado: (2020)

What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004)

What we know so far
Publicado: (2021)

Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis
por: Alshaikh, Faisal Salman, et al.
Publicado: (2022)

Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?
por: Leonel Almeida, Pedro, et al.
Publicado: (2018)

Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021)

The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design
por: Baker, Amanj, et al.
Publicado: (2015)

Estimated indirect costs of haemodialysis versus peritoneal dialysis from a patients’ perspective at an Academic Hospital in Pretoria, South Africa
por: Moalosi, Kotulo, et al.
Publicado: (2023)

Autoimmune pancreatitis: What we know so far
por: Masood, Muaaz
Publicado: (2021)

Incremental Hemodialysis: What We Know so Far
por: Soi, Vivek, et al.
Publicado: (2022)

Monkeypox transmission—what we know so far
por: Venkatesan, Priya
Publicado: (2022)

Amyloidogenesis: What Do We Know So Far?
por: Alraawi, Zeina, et al.
Publicado: (2022)

Moebius Syndrome: What We Know So Far
por: Zaidi, Syed Muhammad Hussain, et al.
Publicado: (2023)

Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System
por: Konoshita, Tadashi
Publicado: (2011)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Antimicrobial Stewardship Activities in Public Healthcare Facilities in South Africa: A Baseline for Future Direction
por: Engler, Deirdré, et al.
Publicado: (2021)

Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study
por: Schmidt, Carlien, et al.
Publicado: (2023)

Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far?
por: Schebb, Nils Helge, et al.
Publicado: (2022)

Virulence of newcastle disease virus: what is known so far?
por: Dortmans, Jos CFM, et al.
Publicado: (2011)

The emotional attentional blink: what we know so far
por: McHugo, Maureen, et al.
Publicado: (2013)

Ketogenic Diet and Epilepsy: What We Know So Far
por: D’Andrea Meira, Isabella, et al.
Publicado: (2019)

Thunderstorm-triggered asthma: what we know so far
por: Harun, Nur-Shirin, et al.
Publicado: (2019)

Diet in the Treatment of Epilepsy: What We Know So Far
por: Verrotti, Alberto, et al.
Publicado: (2020)

Coronavirus advice for associates: what we know so far
por: Goldman, James
Publicado: (2020)

Smoking and COVID-19: What we know so far
por: Shastri, Madhur D., et al.
Publicado: (2021)

COVID-19 and cancer: what we know so far
por: Sidaway, Peter
Publicado: (2020)

COVID-19: What We Have Learned So Far
por: Clifford, Theresa
Publicado: (2020)

Eosinopenia in COVID-19: What we missed so far?
por: Davido, Benjamin, et al.
Publicado: (2021)

Neuroproteomics in Epilepsy: What Do We Know so Far?
por: do Canto, Amanda M., et al.
Publicado: (2021)

Cholangiocarcinoma and liver transplantation: What we know so far?
por: Safarpour, Ali Reza, et al.
Publicado: (2021)

Carotid Artery Calcification: What We Know So Far
por: Ahmed, Madeeha, et al.
Publicado: (2021)

Update on omicron variant: What we know so far
por: Choudhary, Gajendra, et al.
Publicado: (2022)

COVID-19 and Myositis: What We Know So Far
por: Saud, Ahmad, et al.
Publicado: (2021)

Pediatric Myocarditis: What Have We Learnt So Far?
por: Pomiato, Elettra, et al.
Publicado: (2022)

Dr. Fly’s Letter, and What Has Come of It,—So Far
Publicado: (1909)

Eosinophilic Esophagitis—What Do We Know So Far?
por: Wąsik, Jakub, et al.
Publicado: (2023)

HIV and neoplasms: What do we know so far?
por: de Souza, Thais Faria, et al.
Publicado: (2023)

Fibrocartilaginous dysplasia: What do we know so far?
por: Alshalan, Asma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_006ufkv1oruf00l7l40d11qo8i